BioStock: Interim results from Dicot’s phase I study to be released earlier than expected
Dicot’s phase I study is progressing well and the first results are now expected to be presented as early as the beginning of next year. This is earlier than the company first estimated. BioStock reached out to CEO Elin Trampe to find out what this means for the project and what she sees ahead of her when it’s time to put 2023 behind her.
Read the full article at biostock.se:
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se